Autolus Therapeutics PLC (AUTL) Actualités

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Form 8-K - Current report

Autolus Therapeutics Announces Changes to its Board of Directors

-  Appointment of Elisabeth (“Lis”) Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22...

Form 8-K - Current report

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall...

Form 8-K - Current report

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory...

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMTReview of pooled analysis...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Autolus Therapeutics announces participation in upcoming conferences

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

obe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II study AUTO8: oral presentation of...

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute...